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Summary 
Crohn’s disease (CD) is associated with an ecological imbalance of the intestinal microbiota, 
consisting of hundreds of species. The underlying complexity as well as individual differences 
between patients contributes to the difficulty to define a standardized treatment. Computational 
modeling can systematically investigate metabolic interactions between gut microbes to unravel 
novel mechanistic insights. In this study, we integrated metagenomic data of CD patients and 
healthy controls with genome-scale metabolic models into personalized in silico microbiotas. We 
predicted short chain fatty acid (SFCA) levels for patients and controls, which were overall 
congruent with experimental findings. As an emergent property, low concentrations of SCFA were 
predicted for CD patients and the SCFA signatures were unique to each patient. Consequently, 
we suggest personalized dietary treatments that could improve each patient’s SCFA levels. The 
underlying modeling approach could aid clinical practice to find novel dietary treatment and guide 
recovery by rationally proposing food aliments. 
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Introduction 
The human gut microbiota is composed of thousand different bacterial species with a large 
functional diversity that surpasses the human genome in terms of the collective gene pool (Qin et 
al., 2010). Health promoting functions of the gut microbiota include the breakdown of otherwise 
indigestible dietary fibers and production of short chain fatty acids (SCFA) utilized by the human 
host (den Besten et al., 2013b). 
Various human diseases, including inflammatory bowel disease (IBD), are associated with 
a loss of functional and taxonomic diversity of the gut microbiota (Qin et al., 2010). The main 
symptom of IBD is inflammation of the gut epithelium (Khor et al., 2011). Depending on the site 
of inflammation, IBD is distinguished in ulcerative colitis, which primarily affects the colon, and 
Crohn’s disease (CD), in which different sites can be affected. Non-invasive treatments for CD 
include the intake of antibiotics (Prantera et al., 1996) and steroid therapies, which suppress the 
immune system (Van Dullemen et al., 1995). In addition, dietary change with a defined formula is 
used to ease the symptoms of the disease (Wilschanski et al., 1996). However, the success of 
these diet formulas varies between patients (Griffiths et al., 1995). Additionally, after remission, 
patients have difficulties in finding an appropriate diet and often experience relapse. Considering 
the metabolic relevance of the human gut microbiota, it has been suggested that the dietary 
formula effects and reshapes the microbiota (Kaakoush et al., 2015). Overall, the microbial 
diversity is decreased in CD patients. A shortage of SCFAs (Huda-Faujan et al., 2010) coincides 
with a decreased abundance of fermenting Firmicutes bacteria (Manichanh et al., 2006). Microbial 
SCFAs have been recognized as important modulators of the immune system and as a nutrition 
source (Guarner and Malagelada, 2003). Butyrate, for example, is taken up as an additional 
energy source by the host (Donohoe et al., 2011), contributes to epithelial barrier integrity (Peng 
et al., 2007), and stimulates the immune system (Furusawa et al., 2013). CD patients suffer from 
a low butyrate concentration (De Preter et al., 2013), but its dietary supplementation can revert 
many of the IBD symptoms (Sabatino et al., 2005), highlighting the relevance of this particular 
SCFA in CD. 
Given that the human gut microbiota is a complex microbial community with many different 
microbes that have varying metabolic potentials and substrate affinities (Bauer et al., 2015), it 
becomes difficult to track the manifold ecological interactions that differ between CD patients and 
healthy individuals. Meta-omics approaches are generally used to characterize the microbiota 
and its metabolic potential (Zoetendal et al., 2008). However, these top-down approaches do not 
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provide mechanistic insights on the resilience of the microbiota and how perturbations, such as 
dietary treatments, may affect the system as a whole.  
Bottom-up systems biology approaches can mechanistically describe biological systems 
and make biologically relevant predictions. In particular, constraint-based reconstruction and 
analysis (COBRA) has been successfully applied to model the metabolism of different species 
and make predictions on how perturbations affect the metabolic phenotype (Orth et al., 2010). 
Briefly, genome-scale metabolic reconstructions are represented by the complete set of 
biochemical reactions derived from a genome annotation and organism-specific literature in a 
stoichiometric accurate manner (Thiele and Palsson, 2010). Such high-quality manually-curated 
metabolic reconstructions are available for organisms from all three domains of life, such as E. 
coli (O'brien et al., 2013), yeast (Nookaew et al., 2011), and human (e.g., (Thiele et al., 2013b)). 
Through the application of specific constraints (e.g., nutrient availability), the metabolic 
reconstructions can be converted into condition-specific models, which predict the reaction flux 
rates and growth yield under a given objective that is optimized using flux balance analysis (FBA) 
(Orth et al., 2010). In a recent publication (Bauer et al., 2017), we combined FBA with agent based 
modeling to simulate the ecology of microbial communities through the BacArena framework. 
Based on dietary metabolites in the environment, the metabolic models are constrained to 
simulate the metabolic states of each species, optimizing their growth yield. Metabolic interactions 
emerge from the exchange of metabolites between species and the environment. These 
interactions can influence the metabolite concentration and the microbial community by inducing 
cross-feeding or resource competition. Such COBRA-based approaches provide a powerful mean 
to investigate mechanistic links in complex biological systems, such as the human gut microbiota. 
A recent study on pediatric CD sequenced the metagenomes of a North American cohort 
consisting of 26 healthy controls and 85 patients newly diagnosed with CD (Lewis et al., 2015). 
In their study, the authors could distinguish two clusters of patients: A cluster of 57 patients, which 
had a microbiota composition similar to the healthy controls, and a cluster of 28 patients that had 
a distinguished dysbiotic microbiota. Compared to controls, these dysbiotic patients had a strongly 
differing functional and microbial abundance profile. 
Here, we retrieved the original metagenomic data of the 26 healthy controls and 28 
dysbiotic patients (Lewis et al., 2015) to simulate personalized in silico microbiotas with BacArena. 
We demonstrate that the simulated metabolic differences between patients and controls are 
congruent with experimental findings. We further show that predicted individual specific SCFA 
signatures are unique to each patient. Based on these results, we then predict personalized 
dietary treatments that would improve the SCFA concentrations of each patient. With this work, 
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we demonstrate the added value of performing computational modeling in conjunction with high-
throughput data of individual microbiotas to predict mechanism-based personalized dietary 
intervention strategies for CD patients.  
Results 
The aim of the present study was to predict in silico novel personalized dietary treatments for CD 
and investigate individual differences. We simulated personalized in silico microbiotas consisting 
of hundreds microbial metabolic models as defined by published metagenomic data of healthy 
controls and CD patients (Lewis et al., 2015) using a novel computational modeling approach 
(Bauer et al., 2017) in which we combined FBA with agent based modeling to simulate the ecology 
of microbial communities through the BacArena framework. Based on dietary metabolites in the 
environment, the metabolic models are constrained to simulate the metabolic states of each 
species, optimizing their growth yield. Metabolic interactions emerge from the exchange of 
metabolites between species and the environment. These interactions can be used to gain further 
insight into metabolic differences that may contribute to CD and to propose modeling-assisted 
dietary intervention strategies for CD patients (Figure 1). We describe differences between 
healthy controls and CD patients based on SCFAs as well as microbial abundances, which we 
validated with existing experimental knowledge. Individual differences within patients and controls 
were assessed to find the SCFA signature specific to each individual microbiota. Based on the 
individual microbiotas, personalized dietary treatments, such as supplementation of pectin and 
different glycans, were predicted to equilibrate the SCFA concentrations and promote healthier 
SCFA concentrations. Taken together, our work demonstrates the use of computational modeling 
to integrate existing high-throughput data of individual microbiotas and mechanistically predict 
novel personalized dietary treatments for CD.  
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Figure 1: Computational framework used to create personalized metabolic models of gut 
microbial communities. Published metagenomic data were integrated into an in silico microbiota model 
for each CD patient and healthy control to simulate emergent metabolite concentrations. 
Microbial differences between healthy controls and CD patients 
We ensured that our computational workflow (Figure 1) would not alter the reported 
microbial differences between healthy controls and of dysbiotic CD patients (Lewis et al., 2015). 
The workflow mapped the published metagenomic data of healthy controls and CD patients onto 
the genome sequences of the 773 gut microbial strains, for which metabolic reconstructions were 
available (Magnusdottir et al., 2016). In average, 283 +/- 240 of the 773 microbial strains were 
covered in the personalized in silico microbiota (Figure S1). Notably, the smallest in silico 
microbiota contained only eight microbes, while the biggest had 713 of the 773 microbial strains. 
There were seven out of 54 in silico microbiotas that had less than 40 of the 773 microbes. While 
CD patients had generally less microbes, there were also some healthy controls with less than 40 
microbes and some CD patients with more than 600 microbes (Figure S1). Overall, the 
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personalized in silico microbiota captured 73.5 +/- 16 % of the relative microbial abundance from 
the original metagenomic reads. We could observe a clear separation of the healthy controls and 
CD patients when assessing the microbial differences based on microbial abundances captured 
by the in silico microbiota (Figure 2A), which was independent on the used similarity metrics 
(Figure S2). The most pronounced differences between the healthy and the CD individuals were 
due to significantly higher abundance of Bacilli and Gammaproteobacteria (p<0.05, Wilcoxon 
rank-sum test) and significantly lower abundance of Bacteroidia and Clostridia (p<0.001, 
Wilcoxon rank-sum test) in CD patients (Figure 2D).  
 
Figure 2: Metabolic and microbial group variability between healthy controls and Crohn’s disease 
patients. Similarities were assessed based on a principle coordinate analysis (PCoA) of the reaction 
content with jaccard distance (A), mapped reads with bray curtis dissimilarity (B), and simulated 
abundances with bray curtis dissimilarity (C). Based on the simulation, relative abundances (D) and 
metabolite concentrations of fermentation products (E) were compared (p-value determined by Wilcoxon 
rank-sum test). Microbial metabolic activities were displayed as the total population flux (F). 
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We then simulated the personalized in silico microbiota, which were inoculated with 500 
microbes on a grid with 10,000 cells for 24 hours in the BacArena framework and analyzed 
whether the microbial abundances changed compared to the initial (metagenomic data driven) 
abundances. At the end of the simulation, the grid was populated by an average of 5902 +/- 1743 
microbes corresponding to an average grid occupation of 59 +/- 17 %. Overall, the simulated 
abundances recapitulate the initial microbial differences, demonstrating that the in silico 
microbiotas were stable over time in BacArena (Figure 2B). However, the abundance ratios of 
four out of 28 genera were consistently higher in CD patients based on the simulated abundance, 
but lower based on the mapped data (Figure 3A). In contrast, the mapped abundance data 
showed good agreement with the abundances reported in the original study (Figure 3A, Figure 
S3). This discrepancy can be explained by the CD patients having a lower diversity of microbes, 
which led to a higher predicted abundance for the present genera.  
 
Figure 3: Qualitative comparison of simulation results with experimental values. Experimental 
relative abundances of microbial genera (A) were retrieved from the original study (Lewis et al., 2015) 
and compared with the abundances based on the mapped reads and simulations (t=24h). (B) Metabolite 
concentrations were retrieved from an independent experimental study (Hove and Mortensen, 1995) and 
compared with the simulations (t=24h) based on the mean concentration ratios of healthy controls and 
CD patients. 
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Taken together, our workflow recapitulates the reported microbial differences between 
controls and CD patients (Lewis et al., 2015). Furthermore, the simulation results of the 
personalized in silico microbiota in BacArena illustrate that these microbes can also co-exist, in a 
similar relative abundance, as stable microbial communities in silico. 
Emergent metabolic differences between healthy controls and CD 
patients 
We investigated whether the difference in microbial abundance in the personalized in silico 
microbiota also corresponded to differences in metabolic repertoires. That is: Are there microbes 
in some of the personalized in silico microbiota that are unique and may help to distinguish healthy 
and CD microbiota? In average, each personalized in silico microbiota consisted of 3,332,957 +/- 
285,848 metabolic reactions belonging to 3,036 +/- 424 unique metabolic reactions. The presence 
and absence pattern of the unique reactions in the in silico microbiota varied between individuals 
as well as between the two groups (Figure 2C). Interestingly, based on the reaction content, the 
first two principal components explained almost 80% of the variation in the data (Figure 2C), and 
were mainly driven by the presence of transport reactions for fibers (Table S1). The observed 
reaction based separation is consistent with the aforementioned differences in microbial classes 
(Figure 2D) and the distinct fiber metabolizing properties of Bacteroides.  
SCFAs are important energy precursors and interact with the human immune system 
(Furusawa et al., 2013). We analyzed the secretion of SCFAs after 24 hours by each personalized 
in silico microbiota, consisting of a myriad microbial models that can individually consume and 
secrete the SCFAs, to establish whether known microbiota-level differences in SCFA production 
could be reproduced by our computational modeling approach. The SCFAs butyrate, propionate, 
isobutyrate, and acetate were significantly lower in CD patients (p<0.05, Wilcoxon rank-sum test, 
Figure 2E). Only L-lactate levels were slightly higher in CD patients. To check for the validity of 
the simulated metabolite concentrations, we compared our results with an independent 
experimental study (Hove and Mortensen, 1995). The qualitative difference between CD patients 
and healthy controls were consistent with our simulations (Figure 3B). However, the predicted 
concentrations of butyrate and propionate were three times higher in controls than in CD patients 
(Figure 3B), which is much higher than the reported difference, probably due to the absence of 
the host cells in our model setup that can take up butyrate and propionate produced by the 
microbiota (den Besten et al., 2013a). Overall, our results confirm that the personalized in silico 
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microbiotas also recapitulate known differences in SCFA production levels in healthy and CD 
individuals. 
An advantage of using computational modeling is that we can determine which microbes, 
or microbial classes, in the in silico microbiota caused the predicted differences in SCFA 
production. Therefore, we analyzed the summed uptake and secretion fluxes of each microbial 
class in the personalized in silico microbiota. We found that Clostridia were responsible for the 
production of 50% of the total butyrate, Bacteroidia produced almost 100% of the total propionate 
and about 10% of the total isobutyrate, Bacilli produced small quantities (<5% of the total 
concentration) of L-lactate, and Gammaproteobacteria produced almost 50% of the total acetate 
(Figure 2F). Notably, in healthy controls, acetate was taken up by Clostridia illustrating a cross-
feeding mechanism between Gammaproteobacteria and Clostridia. These results demonstrated 
how changes in representatives of the main microbial classes can result in differences in SCFA 
production capabilities that differ significantly between healthy controls and CD patients. 
SCFA production profiles are patient-specific  
The original metagenomic study (Lewis et al., 2015) reported the most distinct microbial 
differences between the healthy controls and the CD patients but also variability within the groups. 
Accordingly, the simulated relative microbial abundance also varied between the individuals 
(Figure 4, left). We next investigated how much the predicted SFCA production capability varied 
between CD patients. Two (CD10, CD11) out of 28 CD patients had butyrate levels that were 
comparable to the mean of healthy controls (mean concentration of 7.5 and 25.8 mM for CD and 
controls respectively). This could be explained by the higher metabolic activity of Clostridia 
species in these patients (Figure 4, right). In three cases (CD2, CD4, CD22), the concentration of 
isobutyrate was higher in CD patients (Figure 4) compared to the mean concentration in healthy 
controls (mean concentration of 4.9 and 7.1 mM for CD and controls respectively). Two of these 
patients (CD2, CD22) also had propionate levels comparable to the mean of healthy controls 
(mean concentration of 25 and 87.9 mM for CD and controls respectively), which is congruent 
with the high metabolic activity of isobutyrate and propionate producing Bacteroides species 
(Figure 4, right). Twelve out of the 28 patients showed increased L-lactate concentrations (mean 
concentration of 0.7 and 0.3 mM for CD and controls respectively), which can be attributed to the 
metabolic activity of Bacilli and other taxa (Figure 4). This is also congruent with the observation, 
that CD patients had an overall higher L-lactate concentration (Figure 2E). Five patients (CD11, 
CD16, CD17, CD19, and CD25) showed acetate levels that were comparable to the mean of 
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healthy controls (mean concentration of 21.1 and 32.2 mM for CD and controls respectively). This 
can be mostly attributed to the metabolic activity of Bacilli and Gammaproteobacteria (Figure 4, 
right). Overall, these results indicated that every patient has a specific signature of SCFAs, in 
which some metabolites have levels comparable to healthy controls. This observation can be 
explained by the metabolic activity of the present microbiota, indicating that metabolic stimulation 
of the native CD microbiota may be able to revert some of the differences between CD and healthy 
controls. 
 
Figure 4: Individual variability between CD patients and healthy controls. The presence of different 
microbes is indicated by a gray color and the relative abundance by a blue color scale. Microbial taxa 
are based on the class level. Predicted metabolite concentrations are based on simulations. The 
microbial contribution to the concentrations are based on metabolic fluxes. 
Personalized dietary intervention strategies to normalize SCFA 
production capabilities of the personalized in silico microbiota  
Defined dietary regimes are one possible treatment strategy for CD patients (Wilschanski 
et al., 1996). However, the success of this treatment varies between CD patients (den Besten et 
al., 2013a). As butyrate is often low in CD patients and its dietary supplementation has been 
reported to ease gastrointestinal symptoms of CD patients (Sabatino et al., 2005), we investigated 
whether we could design personalized dietary interventions that would restore the SCFA 
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production to levels commonly reported in healthy individuals. We approached this problem by 
predicting first whether increasing each dietary compound, present in the in silico rich diet, could 
individually lead to a more healthy level of each of the five SCFAs in any microbial model present 
in a given CD patient in silico microbiota (Figure 5A). Interestingly, the number of the predicted 
dietary metabolites to be supplemented was highly specific for each patient and ranged between 
1 and 55 metabolites (median of 19 metabolites) (Figure 5B). For four out of the 28 CD patients, 
our described prediction approach did not identify any metabolites that could normalize the 
production of any SCFA. These four patients had a higher abundance of Gammaproteobacteria 
and Bacilli, while major SCFA producers, belonging mostly to Bacteroidetes and Clostridia were 
largely absent. For the remaining 24 CD patients, the most prominent category of the predicted 
metabolites were mucus glycans and glycosaminoglycans (Figure 5B). In particular, pectin 
supplementation was predicted to be a good dietary supplement for 17 out of 24 CD patients 
(Figure S4). Other prevalent metabolites included various specific human produced mucus 
glycans and hepan/hyaluronan proteoglycan degradation products as well as plant-derived larch 
arabinogalactan, lavanbiose, and amylose. 
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Figure 5: Individual treatment prediction for each CD patient. For the prediction of treatment 
metabolites (A), single metabolic models of microbes for each patient were optimized for the production 
of the target metabolites with iterative dietary additions. Panel (B) shows broader categories of the 
predicted metabolites and (C) shows the response (metabolite increase of 25%) of each patient in purple. 
Panel (D) and (E) show the relative abundance and metabolite concentrations. 
 
We then added all of these identified metabolites to each of the personalized in silico 
microbiota to ensure that the community could also produce healthier SCFA levels. Each 
personalized in silico microbiota was simulated for 24 hours in the personalized supplemented 
diets. The success of the in silico dietary interventions varied between the patients (Figure 5C). 
Overall, the most successful individual metabolite level restoration was obtained for butyrate, 
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propionate, and acetate, whereas the in silico treatment was less successful for isobutyrate and 
L-lactate (Figure 5C). Overall, the SCFA concentration differences between CD patients and 
healthy controls (Figure 5D) were also improved with respect to butyrate, propionate, and acetate, 
whereas isobutyrate and L-lactate did not show improved levels compared to the untreated 
concentrations (Figure 5D). The in silico treatments had only small effects on the relative species 
abundances in the personalized in silico microbiota as they were not able to restore a more 
healthy ratio of microbial species (Figure 5E) due to the dysbiotic patients lacking the relevant 
microbes found in healthy individuals. Therefore, our results showed quantitatively improved 
levels of SCFAs on the individual patient level as well as on the differences between patients and 
healthy controls. To re-establish a healthier microbiota composition, we would need to account 
for food-borne microbes or probiotics in addition to the dietary treatment. 
Discussion 
We created personalized in silico microbiota of healthy controls and CD patients by integrating 
metagenomic data into a bottom-up systems biology framework (Figure 1). Recent approaches 
have successfully integrated metagenomic data to model the ecological dynamics of the human 
gut microbiota (Bashan et al., 2016) but lack the metabolic aspect, which plays an important role 
for human health and disease (Tremaroli and Bäckhed, 2012). Therefore, the added benefit of 
our modeling approach is that we combine metabolism and ecology to investigate the metabolic 
activity of the human gut microbiota. 
To find strong differences between CD patients and healthy controls, we selected data of 
dysbiotic patients that were defined by their microbial distance to healthy controls (Lewis et al., 
2015). Expectedly, we could reproduce the microbial differences originally reported in the study 
(Figure 2A). Moreover, our reference based assessment was consistent with the reference 
independent analysis in the original study (Figure 3A), which further demonstrates that the set of 
773 AGORA microbes capture the most common human gut microbes (Magnusdottir et al., 2016). 
When comparing the abundance of specific genera (Figure 3A), the community simulations 
predict differing ratios for four out of 28 genera, which indicates a minor variability in the 
simulations that did not affect the overall differences (Figure 2B). The main microbial differences 
between CD patients and healthy controls can be attributed to a decreased abundance of 
Bacteroidia and Clostridia as well as an increased abundance of Bacilli and 
Gammaproteobacteria in CD patients (Figure 2D), which was in accordance with an independent 
experimental study (Kaakoush et al., 2012) and characteristic for a dysbiotic microbiota. Our 
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results therefore capture strongly dysbiotic CD microbiotas, which is, however, only one specific 
case of CD (Lewis et al., 2015). This approach allows us to address fundamental questions in CD 
dysbiosis and to mechanistically describe how the microbiota can shape metabolite 
concentrations, which is less understood so far. 
The simulated SCFA concentrations represent emergent properties of our models that 
could not be achieved by the metagenomic data alone. Therefore, we could simulate clinical 
relevant metabolite concentrations, known to be differentially regulated in CD (Hove and 
Mortensen, 1995). Interestingly, we could see differences in SCFA levels between healthy 
controls and CD patients (Figure 2E). In particular, higher concentrations of acetate, propionate, 
butyrate, and isobutyrate as well as a lower concentration of L-Lactate in controls (Figure 2E). 
We could also validate these qualitative differences with experimental literature (Hove and 
Mortensen, 1995) (Figure 3B). Based on the quantitative ratios between controls and patients, 
butyrate and propionate were higher in our simulations than in experiments (Figure 3B). This 
apparent discrepancy could be explained by the uptake of butyrate and propionate by the host 
(den Besten et al., 2013a), which we did not include and is therefore a limitation of our current 
modeling approach. SCFAs, in general, have been associated with healthy gut functions, such as 
energy conversion of the host as well as immune stimulation (Guarner and Malagelada, 2003). 
Butyrate, in particular, mediates the immune system (Furusawa et al., 2013) and influences the 
tight junctions between epithelial cells (Peng et al., 2007). Moreover, butyrate, as well as 
propionate, are carbon sources for colonocytes (Clausen and Mortensen, 1995; Roediger, 1982). 
Taken together, the added value of our modeling approach is that we can predict these qualitative 
changes in SCFA levels, which we can attribute to specific microbial metabolic activity. 
We identified which microbes are responsible for the production of the SCFA (Figure 2F). 
Clostridia produced mainly butyrate explaining its lower concentration in CD patients (Figure 2E), 
who had generally lower Clostridia abundances (Figure 2D). The Clostridia Faecalibacterium and 
Roseburia are known to be the main butyrate producers (Machiels et al., 2013). Interestingly, 
these two Clostridia were decreased in abundance in CD patients (Figure 3B). We identified novel 
metabolic interaction patterns, such as the consumption of acetate by Clostridia (Figure 2F). In 
vitro experiments have demonstrated cross-feeding interactions between Clostridia and 
Bifidobacterium species (Belenguer et al., 2006). Based on our simulation, we suggest that these 
interactions take also place in an ecologically complex microbiota and that they are of high 
relevance in the human gut. These metabolic interactions link microbes with metabolites and 
demonstrate that we capture in silico the gut microbiota as a whole.  
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Our personalized in silico microbiota modeling approach permitted the investigation of 
individual differences between CD patients and healthy controls (Figure 4). Overall, we found that 
healthy controls have a higher diversity of microbes than CD patients, which is also confirmed by 
experimental knowledge (Manichanh et al., 2006). Consequently, controls have more comparable 
SCFA levels (Figure 4), indicating metabolic consistency through functional redundancy of 
microbes (Human Microbiome Project Consortium, 2012). Interestingly, some patients had some 
SCFA but not all levels comparable with the controls, which could be attributed to a higher 
metabolic activity of health relevant microbes in those patients (Figure 4). One could speculate 
that the microbiota of CD patients can compensate some metabolic differences but lacked 
functional redundancy and diversity to consistently establish a healthy SCFA signature (Figure 
4). This observation further underlines the importance of a diverse microbiota, which can 
complement potential metabolic shortcomings between microbes and consistently produce 
SCFAs. Further studies could investigate the importance of keystone species in this context, 
which have a low abundance but high metabolic activity and thus ecological relevance (Trosvik 
and Muinck, 2015). 
In our in silico treatment predictions, we take the individual factors into account by 
designing dietary supplements that would compensate the individual differences (Figure 5A). 
Most of the predicted treatment metabolites were mucus glycans, glycosaminoglycans, and plant 
polysaccharides (Figure 5B), further indicating that fibers are relevant in shaping the gut 
microbiota metabolism (Koropatkin et al., 2012; Maxwell et al., 2012). Particularly, pectin was 
predicted as a potential treatment for the majority of patients, which further points towards the 
dietary relevance of this compound (Maxwell et al., 2012). Plant fibers and host glycans can 
influence the gut microbiota by stimulating Clostridia and Bacteroidia species (Flint et al., 2008), 
which produce butyrate and propionate, respectively (Figure 2F). Interestingly, the predicted 
metabolite cocktails were different for each patient (Figure 5B, Figure S4). In clinical practice, a 
standard dietary formula in form of exclusive enteral nutrition is used to treat patients with CD 
(Wilschanski et al., 1996). However, not every patient responds equally well to different diet 
formulations, which vary in their fiber content (Lien et al., 1996). Current knowledge is limited 
when defining personalized diets because of the complexity of the human gut microbiota and its 
intricate response to different diets. Some patients suffer from relapse when switching to a normal 
diet after successful remission (Belluzzi et al., 1996). In such cases, our modeling-based 
predictions could give novel directions on aliments based on a patient’s microbiota. Finally, a 
dietary treatment strategy for an individual is not likely to be static. Using computational modeling 
in conjunction with metagenomic data, the dietary treatment could be readily redefined and 
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adjusted to match the patient’s need. To our knowledge, such modeling-guided dietary treatment 
approach is not available yet for Crohn’s disease patients. As a next step, our predictions need 
to be validated in a nutritional trial. Then, our systematic approach to defining personalized 
nutrition therapies could guide clinicians and nutritionists in designing new, personalized diet-
based treatments.  
Testing our in silico dietary treatments on each patient's’ microbiota, we found an 
improvement in SCFA levels. Butyrate, propionate, and acetate showed an overall success in 
shifting levels, while isobutyrate and L-lactate were less successful (Figure 5C, 5E), since those 
SCFAs only had a minor difference between controls and patients (Figure 2E). The overall 
microbe abundance did also not shift significantly in the treatment condition (Figure 5D), because 
patients had a lower diversity from the start (Figure 4) and could not acquire the necessary 
microbes to compensate their abundance profile. Further studies could simulate the effect of 
adding specific microbe models as a treatment, which could be integrated in our framework. 
Furthermore, human metabolism could be integrated with the in silico microbiota to investigate 
the reciprocal effect on the host, and, for instance, the effect of colorectal cancer cells that might 
be affected by butyrate concentrations (Sengupta et al., 2006). 
Several studies emphasize the need for computational models to discover novel 
hypothesis and mechanisms for microbiota associated diseases (Biggs et al., 2015; Ji and 
Nielsen, 2015; Thiele et al., 2013a). Our approach introduces metabolism as an additional 
emergent property of the microbiota yielding into novel mechanistic insight of SCFA production 
by microbial communities. So far, our approach ignores for simplicity the spatial component, which 
could have important implications in shaping the ecology and possible metabolic interactions. An 
extension for possible treatment strategies includes the simulation of probiotics and fecal 
transplantation. In fact, our model could be used as an additional workflow for donor optimization 
of fecal transplantation (Pamer, 2014) by finding the most appropriate microbiota. Most 
importantly, the computational modeling approach that we presented here is not limited to the 
application of CD but can be applied to any metagenomic data set and disease with microbial 
dysbiosis. Taken together, we present a powerful, expandable, versatile computational modeling 
approach that permits to yield novel insight into metabolic interactions emerging from 
personalized metagenomic data and to predict personalized dietary intervention strategies. 
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Methods 
Key resources table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Biological Samples     
Metagenomic samples of healthy controls and 
Crohn’s disease patients 
Lewis et al., 2015 SRP057027 
Deposited Data 
Human genome version 38 Genome Reference 
Consortium 
http://www.ncbi.nlm.n
ih.gov/projects/geno
me/assembly/grc/ 
773 metabolic reconstructions (AGORA) Magnusdottir et al., 
2016 
http://vmh.uni.lu/#do
wnloadview  
Software and Algorithms 
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Trimmomatic Bolger et al., 2014 http://www.usadellab.
org/cms/?page=trim
momatic  
Burrows-Wheeler Aligner (BWA) Li et al., 2009 https://sourceforge.n
et/projects/bio-
bwa/files/  
Samtools Li et al., 2009 https://sourceforge.n
et/projects/samtools/f
iles/  
ILOG CPLEX IBM https://www.ibm.com/
bs-
en/marketplace/ibm-
ilog-cplex  
R The R Foundation https://www.r-
project.org/  
R package BacArena Bauer et al., 2017 https://cran.r-
project.org/web/pack
ages/BacArena/index
.html  
R package vegan Oksanen et al., 2009 https://cran.r-
project.org/web/pack
ages/vegan/index.ht
ml  
R package sybil Gelius-Dietrich et al., 
2013 
https://cran.r-
project.org/web/pack
ages/sybil/index.html  
Contact for reagent and resource sharing 
Further information and requests for resources and software should be directed to the 
Lead Contact, Ines Thiele (ines.thiele@uni.lu). 
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Experimental model and subject details 
Paired-end Illumina raw reads of a study on early onset Crohn’s disease (CD) patients 
and healthy controls of a North American cohort (Lewis et al., 2015) were retrieved from NCBI 
SRA under the accession: SRP057027. Based on the studies’ definition of healthy and dysbiotic 
individual microbiotas (Lewis et al., 2015), the samples were selected to a smaller subset of 26 
healthy controls and 28 CD patients to capture the most pronounced differences in the individual 
microbial communities. The healthy controls encompassed 12 females and the average age was 
14.3 years. The CD patients encompassed 13 females and the average age was 13.9 years. 
Read accessions and ids of the used samples can be found in Table S2. 
Method details 
Retrieval of metagenomic data and pre-processing 
Paired-end Illumina raw reads of a study on early onset Crohn’s disease (CD) patients 
and healthy controls of a North American cohort (Lewis et al., 2015) were retrieved from NCBI 
SRA under the accession: SRP057027. Based on the studies’ definition of healthy and dysbiotic 
individual microbiotas (Lewis et al., 2015), the samples were selected to a smaller subset of 26 
healthy controls and 28 CD patients to capture the most pronounced differences in the individual 
microbial communities. The selected patients showed pronounced differences in their functional 
and microbial profile in the original study (Lewis et al., 2015). Furthermore, only the first measured 
time point was selected to represent newly diagnosed and yet untreated microbiotas. The reads 
were quality trimmed using Trimmomatic (Bolger et al., 2014) with default parameters for paired-
end Illumina sequences. To remove human contaminant sequences, the reads which were still 
paired after the quality control were mapped with default parameters using the software BWA (Li 
and Durbin, 2009) to the human genome version 38 
(http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/). 
Metagenomic mapping and abundance estimation 
Using BWA (Li and Durbin, 2009), the pre-processed reads were mapped with default 
parameters onto a reference set of 773 genomes, which were selected according to a previous 
study (Magnusdottir et al., 2016) (see also below). Before mapping, the reference genomes of 
these organisms were combined into one file where each genome is represented as a 
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chromosome. To filter out cross-mapped reads (reads mapped to multiple positions), samtools 
(Li et al., 2009) was used to discard mapped reads with a low-quality score. The coverage per 
genome (number of mapped reads normalized by genome size) was calculated using samtools. 
To reduce the number of false positives, we set a threshold of at least 1% genome coverage for 
each microbe in each human individual. In accordance to another pipeline (Karlsson et al., 2014), 
the resulting coverages were normalized for each individual to obtain the relative microbe 
abundances. 
Microbial metabolic reconstructions 
We retrieved published gut microbial metabolic reconstruction (Magnusdottir et al., 2016) 
from http://vmh.life. These microbes have been chosen according to their prevalence in the 
human gut and the availability of a genome sequences, and they have been extensively curated 
based on available physiological and biochemical data (Magnusdottir et al., 2016). In average, a 
microbial reconstruction consisted of 933 +/- 139 metabolites, 1,198 +/- 241 reactions, and 771 
+/- 262 genes.   
Analysis of mapped abundance and reaction differences 
The mapped microbial abundances for each individual were compared by computing the 
Bray-Curtis similarity and subsequent visualization with principal coordinate analysis (PCoA) 
using the R package vegan (Dixon, 2003). The unique reaction set of personalized in silico 
microbiota was determined by taking the union of all present microbe reactions. These reactions 
were retrieved from the corresponding metabolic models (Magnusdottir et al., 2016) of each 
microbe. PCoA was performed on the metabolic distance between each individual's reaction set 
similar to (Magnusdottir et al., 2016). 
Setup, integration, and simulation of the personalized microbiota models 
In the previous steps, the microbial abundance information for each individual was 
determined. The next step is to integrate this information into a personalized in silico microbiota 
for each person. Therefore, we used a previously established R package for community modeling 
(Bauer et al., 2017), which represents bacteria as individuals in a grid environment that can 
exchange metabolites by secretion and uptake. Multiple species can be integrated into the 
environment with varying number of individuals per species. The dimensions of the two-
dimensional quadratic environment was set 0.025 cm2 with 100 grid cells per side length. This 
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resulted in 10,000 grid cells that could be potentially occupied by the microbes. To allow space 
for the in silico microbial community to grow, only 500 microbes were initially added to the grid 
environment. The relative microbial abundances were used to determine the number of microbes 
to be added per species (e.g., if one species has a relative abundance 0f 0.01, 5 microbes were 
added for this species on the entire grid). In case the calculated number of microbes resulted in 
decimal places, we rounded the final number to the next highest integer. All possible metabolites 
(union of metabolites that can be taken up by each microbe) were added to the environment with 
a minimal concentration of 0.2 µM to provide a rich medium that is consistent between individuals. 
Therefore, metabolite concentrations that emerge from the simulations can be specifically 
attributed to the microbiota of each individual. 
Once the in silico microbiota for each CD patient and healthy control have been setup in 
BacArena, the growth of each microbial model in the microbiota was sequentially for each time 
step. A total of 24 time steps were simulated, one per hour, corresponding to an overall simulation 
time of 24 hours. At each time step, the medium composition of each grid cell was updated as a 
function of the metabolites that were taken up or secreted by the occupying microbes. When a 
certain growth rate of a microbe occupying a grid cell was reached, a neighboring free grid cell 
could be occupied by the microbe. If no neighboring grid cell was available, then cells do not 
duplicate. To reduce the complexity of the model, we simulated a well-mixed environment in which 
metabolite concentrations are uniformly distributed and microbes move randomly.  
The R package sybil (Gelius-Dietrich et al., 2013) was used for constraint based modeling. ILOG 
CPLEX was used as a linear programming solver. The computations were carried out on high 
performance computer clusters. 
Analysis of simulation results 
After the simulation, each personalized in silico microbiota was primarily analyzed in terms 
of the microbe abundance and metabolite concentrations. Since the simulations include temporal 
dynamics with different time points, we chose the last time point (24h) for our analysis and 
comparison between individuals. This allowed the in silico microbial communities enough time to 
consume and produce metabolites, and to reach a steady state. The microbial abundances were 
determined by assessing the number of microbes in each personalized in silico microbiota. The 
vector of microbial abundances was then compared by computing the Bray-Curtis similarity and 
subsequently visualized with PCoA. Abundances of specific taxa were calculated by summing up 
the relative abundances of each corresponding representative. The abundances of the most 
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differing taxa were tested for significant differences between healthy controls and CD patients 
with the Wilcoxon rank-sum test (Wilcoxon, 1945). 
Metabolite concentrations were determined by their molar concentration in the 
environment at the end of the simulation (t=24h). The concentration of the most relevant 
metabolites, butyrate, propionate, isobutyrate, L-lactate, and acetate, were assessed and tested 
for significant differences between the personalized in silico microbiota of healthy controls and of 
CD patients using the Wilcoxon rank-sum test. To investigate the influence of each microbial taxa 
on the metabolite concentrations, we further evaluated the metabolic fluxes of each microbe in 
the personalized in silico microbiota. For each taxa, the reaction fluxes in all corresponding 
microbes were summed up. 
Definition of personalized dietary treatments 
After identifying the metabolic signatures influencing CD and the corresponding microbes 
causing these differences between healthy controls and CD patients, we predicted metabolites 
that could revert these differences. Therefore, we analyzed each genome-scale microbial 
metabolic model separately.  
According to their presence in each personalized in silico microbiota, the set of microbes 
was selectively analyzed for every individual. Each personalized in silico microbiota was then 
simulated in a rich medium containing all possible metabolite with flux uptake constraints of 1 
mmol gDW-1 h-1 and the biomass as well as the production of SCFAs (butyrate, propionate, 
isobutyrate, L-lactate, acetate) were optimized for separately. To enhance the growth of beneficial 
bacteria, we selected metabolites based on the ability of the CD low abundant microbes (e.g., 
Clostridia, Bacteroides) to uptake these nutrients over the CD high abundant microbes (e.g., 
Gammaproteobacteria, Bacilli). We then added the selected metabolites iteratively to the in silico 
medium with a maximal flux uptake constraint of 1000 mmol gDW-1 h-1 to investigate whether the 
fermentation products increased or decreased. Based on these simulations, the added 
metabolites which had a positive effect (recovering metabolite production to healthy levels) were 
then collected and used as the personalized dietary treatment for each individual. 
We tested the effect of the treatment on the personalized in silico microbiota of CD patients 
by adding a 100 times higher concentration of the predicted treatment metabolites to the in silico 
rich diet containing 0.2 µM for each metabolite. The personalized in silico microbiota simulations 
and analyses were then carried out as described above. 
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Quantification and statistical analysis 
Differences between healthy controls and CD patients were assessed with the Wilcoxon 
rank-sum test implemented in R. For the healthy controls our group size was 26 individuals and 
for the CD group 28 individuals. 
Data and software availability 
The scripts to construct and simulate the individual specific microbiota models as well as 
the analysis scripts are available on GitHub: https://github.com/euba/CodeBase  
 
